Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
Document Type
- Doctoral Thesis (22)
Keywords
- DNS-Reparatur (4)
- Enzym (3)
- Staphylococcus aureus (3)
- TFIIH (3)
- Transkriptionsfaktor (3)
- Arzneimitteldesign (2)
- DNA-Reparatur (2)
- Röntgenkristallographie (2)
- Structural Biology (2)
- Transkription (2)
- USP (2)
- Antikörper-Antwort (1)
- Atomic-force-microscopy (1)
- Bauchspeicheldrüsenkrebs (1)
- Benzoate (1)
- Benzoate degradation (1)
- Biologischer Abbau (1)
- CE Proteaes (1)
- Candida albicans (1)
- Chaetomium thermophilum (1)
- Chemotherapie (1)
- Chlamydia trachomatis (1)
- Cholesterinstoffwechsel (1)
- Computational drug design (1)
- Cushing-Syndrom (1)
- DNA Repair (1)
- DNA lesion (1)
- DNA repair (1)
- DNS-Bindung (1)
- DNS-Schaden (1)
- DNS-Schädigung (1)
- DUB (1)
- Diphenylether (1)
- Echinococcus (1)
- Einzel-Molekül (1)
- Enoyl-acyl-carrier-protein-Reductase <Enoyl-[acyl-carrier-protein]-Reductase> (1)
- Fanconi Anemia (1)
- Fanconi-Anämie (1)
- Fettsäurestoffwechsel (1)
- Fuchsbandwurm (1)
- General Transcription Factor II H (1)
- Genome Instability (1)
- Helicasen (1)
- Helikasen (1)
- Herz-Kreislauf-Erkrankung (1)
- Inhibition (1)
- Inhibitor (1)
- Kardiovaskuläre Krankheit (1)
- Komplement <Immunologie> (1)
- Kristallographie (1)
- Kristallstruktur (1)
- MET-T-box riboswitch (1)
- MYC (1)
- Menaquinon-BIosynthese (1)
- Menaquinone Biosynthesis (1)
- Methioninbiosynthese (1)
- Multidrug-Resistenz (1)
- Mutation (1)
- Myc (1)
- Mycobacterium tuberculosis (1)
- Mycobacterium tuberculosis InhA (1)
- N-Myc (1)
- Nucleotide Excision Repair (1)
- Nucleotide excision repair (1)
- Nukleotid-Exzisions-Reparatur (1)
- Oligomerisation (1)
- OmoMYC (1)
- PAF1c (1)
- PRKACA (1)
- Pause Release (1)
- Polo-like kinase 1 (1)
- Proteinkinase A (1)
- Prävention (1)
- Pyrrolidinderivate (1)
- Pyrrolidine carboxamides (1)
- RNA Abbau (1)
- RNA Polymerase II (RNAPII) (1)
- RNA decay (1)
- Rasterionenmikroskop (1)
- Rasterkraft-Mikroskopie (1)
- RecQ helicase (1)
- Rhodopseudomonas palustris (1)
- Rothmund-Thomson-Syndrome (1)
- SEPHCHC Synthase (1)
- Single-molecule (1)
- Ssl1 (1)
- Stammzelle (1)
- Structure-based (1)
- Strukturbiologie (1)
- Tfb4 (1)
- Thiolase (1)
- Transcription Regulation (1)
- Transcription factor (1)
- Transcriptional Stress Response (1)
- Transkription <Genetik> (1)
- Tuberkelbakterium (1)
- Tuberkulose (1)
- Ubiquitin (1)
- Ubiquitin Specific Protease 11 (1)
- Unique Selling Proposition (1)
- Verweildauer (1)
- Virulenzfaktor (1)
- X-ray crystallography (1)
- Xeroderma pigmentosum (1)
- bacterial fatty-acid biosynthesis (1)
- covalent inhibition (1)
- crystallography (1)
- deubiquitinase (1)
- double-strand break repair (1)
- drug repurposing (1)
- enoyl ACP reductase (1)
- enoyl-ACP reductase (1)
- enzyme (1)
- inhibitor residence time (1)
- kardiovaskuläre Risikofaktoren (1)
- methionine biosynthesis (1)
- oligomerization (1)
- p34 (1)
- p44 (1)
- promoter invasion (1)
- pyrrolidine carboxamides (1)
- riboswitch (1)
- structure-based drug design (1)
- transcription elongation factor A (SII)-like 1 (TCEAL1) (1)
Institute
Sonstige beteiligte Institutionen
Biochemical characterization of the TFIIH translocase XPB from \(Chaetomium\) \(thermophilum\)
(2024)
DNA repair and gene expression are two major cellular processes that are fundamental for the maintenance of biological life. Both processes require the enzymatic activity of the super family 2 helicase XBP, which is an integral subunit of the general transcription factor TFIIH. During transcription initiation, XPB catalyzes the initial melting of promoter DNA enabling RNA polymerase II to engage with the coding DNA strand and start gene transcription. In nucleotide excision repair, XPB acts in concert with the other TFIIH helicase XPD causing strand separation around a lesion site. Mutations within the genes encoding XPB or other TFIIH subunits are associated with different cancer types as well as with the autosomal recessive disorders Xeroderma Pigmentosum and trichothiodystrophy and rarely combined features of Xeroderma Pigmentosum and Cockayne syndrome.
In the last few years, great progress has been made towards unraveling the structure of TFIIH and its individual subunits including XPB. These structural insights tremendously improved our understandings with respect to the molecular interactions within this intriguing protein complex. However, the underlying regulation mechanisms that functionally control XPB during transcription and repair remained largely elusive. We thus executed the biochemical characterization of this protein to investigate the functional network that regulates XPB within the scaffold of TFIIH. Due to their enhanced stability compared to the human proteins, we utilized the proteins that originate from the thermophilic fungus Chaetomium thermophilum for this purpose as a model organism for eukaryotic TFIIH.
The present work provides novel insights into the enzymatic function and regulation of XPB. We could show that both, DNA and the TFIIH subunit p52 stimulate XPB’s ATPase activity and that the p52-mediated activity is further boosted by p8, another subunit within TFIIH. Surprisingly, DNA can activate XPB’s ATPase activity to a greater extent than its TFIIH interaction partners p52/p8, but when both, i.e. p52/p8 and DNA are present at the same time, p52 dominates the activation and the enzymatic speed is maintained at the level observed through the sole activation of p52/p8. We thus defined p52 as the master regulator of XPB that simultaneously activates and represses XPB’s enzymatic activity. Based on a correlative mutagenesis study of the main interface between p52 and XPB that was set into context with recent structural data, a model for the p52-mediated activation and speed limitation of XPB’s ATPase was proposed. The research on XPB’s ATPase was expanded with the investigation of the inhibition mechanism of XPB’s ATPase via the natural compound Triptolide. Furthermore, we investigated XPB’s DNA translocase function and could observe that XPB can only perform its translocase movement when it is fully incorporated into core TFIIH and this translocase movement is further enhanced by the nucleotide excision repair factor XPA. Fluorescence polarization measurements with nucleotide analogues revealed that XPB displays the highest affinity towards DNA in the ADP + Pi bound state and its binding is weakened when ADP is bound or the nucleotide is dissociated from the enzyme, suggesting a movement on the DNA during the distinct states of the ATPase cycle. Finally, the well-known and highly conserved RED motif was found to be the crucial element in XPB to enable this translocase movement. Combined, the data presented in this work provide novel insights into the intricate regulation network that controls XPB’s enzymatic activity within TFIIH and furthermore show that XPB’s enzymatic activity is tightly controlled by various factors.
Ubiquitination is an important post-translational modification that maintains cellular homeostasis by regulating various biological processes. Deubiquitinases (DUBs) are enzymes that reverse the ubiquitination process by catalyzing the removal of ubiquitin from a substrate. Abnormal expression or function of DUBs is often associated with the onset and progression of various diseases, including cancer. Ubiquitin specific proteases (USPs), which constitute the largest family of DUBs in humans, have become the center of interest as potential targets in cancer therapy as many of them display increased activity or are overexpressed in a range of malignant tumors or the tumor microenvironment.
Two related members of the USP family, USP28 and USP25, share high sequence identities but play diverse biological roles. USP28 regulates cell proliferation, oncogenesis, DNA damage repair and apoptosis, whereas USP25 is involved in the anti-viral response, innate immunity and ER-associated degradation in addition to carcinogenesis. USP28 and USP25 also exhibit different oligomeric states – while USP28 is a constitutively active dimer, USP25 assumes an auto-inhibited tetrameric structure. The catalytic domains of both USP28 and USP25 comprise the canonical, globular USP-domain but contain an additional, extended insertion site called USP25/28 catalytic domain inserted domain (UCID) that mediates oligomerization of the proteins. Disruption of the USP25 tetramer leads to the formation of an activated dimeric protein. However, it is still not clear what triggers its activation.
Due to their role in maintaining and stabilizing numerous oncoproteins, USP28 and USP25 have emerged as interesting candidates for anti-cancer therapy. Recent advances in small-molecular inhibitor development have led to the discovery of relatively potent inhibitors of USP28 and USP25. This thesis focuses on the structural elucidation of USP28 and the biochemical characterization of USP28/USP25, both in complex with representatives of three out of the eight compound classes reported as USP28/USP25-specific inhibitors. The crystal structures of USP28 in complex with the AZ compounds, Vismodegib and FT206 reveal that all three inhibitor classes bind into the same allosteric pocket distant from the catalytic center, located between the palm and the thumb subdomains (the S1-site). Intriguingly, this binding pocket is identical to the UCID-tip binding interface in the USP25 tetramer, rendering the protein in a locked, inactive conformation. Formation of the binding pocket in USP28 requires a shift in the helix α5, which induces conformational changes and local distortion of the binding channel that typically accommodates the C-terminal tail of Ubiquitin, thus preventing catalysis and abrogating USP28 activity. The key residues of the USP28-inhibitor binding pocket are highly conserved in USP25. Mutagenesis studies of these residues accompanied by biochemical and biophysical assays confirm the proposed mechanism of inhibition and similar binding to USP25.
This work provides valuable insights into the inhibition mechanism of the small molecule compounds specifically for the DUBs USP28 and USP25. The USP28-inhibitor complex structures offer a framework to develop more specific and potent inhibitors.